Market Overview

Lipodystrophy Syndrome | A Drug Pipeline Analysis Report 2018 | Technavio

Share:

Technavio has announced their latest analysis report on drug pipeline
for lipodystrophy
syndrome
. The report includes a detailed analysis of the
pipeline molecules under investigation within the defined data
collection period to treat lipodystrophy syndrome.

This press release features multimedia. View the full release here:
https://www.businesswire.com/news/home/20180802005796/en/

Technavio has published a new report on the drug development pipeline for lipodystrophy syndrome, in ...

Technavio has published a new report on the drug development pipeline for lipodystrophy syndrome, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report by Technavio
presents a detailed analysis of the market, including regulatory
framework, drug development strategies, recruitment strategies, and key
companies that are expected to play an essential role in the growth of
the market in the future.

This report is available at a USD 1,000 discount for a limited time
only:
View
market snapshot before purchasing

Lipodystrophy syndrome: Market overview

Lipodystrophy syndrome is a genetic or acquired rare disorder, which
results in a fat loss (lipoatrophy) or an abnormal
distribution/accumulation of fat tissues in the body. The severity of
metabolic complications may determine the amount of fat loss.
Lipodystrophy causes various metabolic complications such as insulin
resistance, diabetes mellitus, hypertriglyceridemia, hepatic steatosis,
and dyslipidemia.

According to a senior market research analyst at Technavio, "As per
National Institute of Health, lipodystrophy is a rare disease. The
familial partial lipodystrophy is estimated to be affecting one in one
million people. Women are found to be more affected by familial partial
lipodystrophy as compared to men."

Lipodystrophy syndrome: Segmentation analysis

This pipeline analysis report segments the lipodystrophy syndrome market
based on therapies employed (monotherapy), RoA (oral, subcutaneous, and
intravenous+subcutaneous), therapeutic modality (biological,
oligonucleotides, small molecule, and recombinant protein), targets
(apolipoprotein C-III, leptin receptor, PPAR, ANGPTL3 protein,
somatotropin receptor, and stearoyl-CoA desaturase), MoA (leptin
receptor modulators, PPAR agonist, ANGPTL3 protein inhibitors,
apolipoprotein C-III inhibitors, gene silencing, somatotropin receptor
agonists, and stearoyl-CoA desaturase modulators), geographical
segmentation (US and Belgium) and recruitment status (active, not
recruiting and recruiting). It provides an in-depth analysis of the
prominent factors influencing the market, including drivers,
opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 33% of the molecules that are
being investigated for the treatment of lipodystrophy syndrome are
biological molecules.

Looking for more information on this market? Request
a free sample report

Technavio's sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio
is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio's report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio's comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team
at media@technavio.com.

View Comments and Join the Discussion!